163 related articles for article (PubMed ID: 9296467)
1. Fragmin in unstable angina pectoris or in non-Q-wave acute myocardial infarction (the FRIC study). Fragmin in Unstable Coronary Artery Disease.
Klein W; Buchwald A; Hillis WS; Monrad S; Sanz G; Turpie AG; van der Meer J; Olaisson E; Undeland S; Ludwig K
Am J Cardiol; 1997 Sep; 80(5A):30E-34E. PubMed ID: 9296467
[TBL] [Abstract][Full Text] [Related]
2. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC).
Klein W; Buchwald A; Hillis SE; Monrad S; Sanz G; Turpie AG; van der Meer J; Olaisson E; Undeland S; Ludwig K
Circulation; 1997 Jul; 96(1):61-8. PubMed ID: 9236418
[TBL] [Abstract][Full Text] [Related]
3. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group.
Lancet; 1996 Mar; 347(9001):561-8. PubMed ID: 8596317
[TBL] [Abstract][Full Text] [Related]
4. Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). FRISC Study Group.
Swahn E; Wallentin L
Am J Cardiol; 1997 Sep; 80(5A):25E-29E. PubMed ID: 9296466
[TBL] [Abstract][Full Text] [Related]
5. Enoxaparin and dalteparin in unstable angina: new indication. Enoxaparin: a reference treatment. Dalteparin: no better than unfractionated heparin.
Prescrire Int; 1999 Jun; 8(41):77-80. PubMed ID: 10558446
[TBL] [Abstract][Full Text] [Related]
6. Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction.
Monrad ES
Am J Cardiol; 2000 Apr; 85(8A):2C-9C. PubMed ID: 10793174
[TBL] [Abstract][Full Text] [Related]
7. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators.
Lancet; 1999 Aug; 354(9180):701-7. PubMed ID: 10475180
[TBL] [Abstract][Full Text] [Related]
8. Low-molecular-weight heparin as a bridge to timely revascularization in unstable coronary artery disease -- an update of the Fragmin during Instability in Coronary Artery Disease II Trial.
Wallentin L
Haemostasis; 2000; 30 Suppl 2():108-13; discussion 106-7. PubMed ID: 11251353
[TBL] [Abstract][Full Text] [Related]
9. Implications of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) study and the results in the context of other trials.
Fox KA
Am J Cardiol; 1999 Sep; 84(5A):26M-31M. PubMed ID: 10505540
[TBL] [Abstract][Full Text] [Related]
10. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).
Eur Heart J; 1999 Nov; 20(21):1553-62. PubMed ID: 10529323
[TBL] [Abstract][Full Text] [Related]
11. New frontiers in the management of unstable coronary artery disease.
Turpie AG
Am J Cardiol; 1997 Sep; 80(5A):21E-24E. PubMed ID: 9296465
[TBL] [Abstract][Full Text] [Related]
12. Acute and prolonged treatment with low-molecular-weight heparin therapy in patients with unstable coronary artery disease.
Husted S; Kher A
Ann Med; 2000 Dec; 32 Suppl 1():53-9. PubMed ID: 11209983
[TBL] [Abstract][Full Text] [Related]
13. Low molecular weight heparin for treatment of acute myocardial infarction (FAMI): Fragmin (dalteparin sodium) in acute myocardial infarction.
Kakkar VV; Iyengar SS; De Lorenzo F; Hargreaves JR; Kadziola ZA;
Indian Heart J; 2000; 52(5):533-9. PubMed ID: 11256775
[TBL] [Abstract][Full Text] [Related]
14. Dalteparin for acute coronary syndromes.
O'Loughlin DC
Heart Dis; 1999; 1(5):329-36. PubMed ID: 11720639
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis.
Antman EM; Cohen M; Radley D; McCabe C; Rush J; Premmereur J; Braunwald E
Circulation; 1999 Oct; 100(15):1602-8. PubMed ID: 10517730
[TBL] [Abstract][Full Text] [Related]
16. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
N Engl J Med; 1997 Aug; 337(7):447-52. PubMed ID: 9250846
[TBL] [Abstract][Full Text] [Related]
17. Low-molecular-weight heparins and unstable angina--current perspectives.
Turpie AG
Haemostasis; 1997; 27 Suppl 1():19-24. PubMed ID: 9439754
[TBL] [Abstract][Full Text] [Related]
18. [Low molecular weight heparin in the treatment of acute coronary syndromes without ST-segment elevation: unstable angina and non-Q-wave myocardial infarction].
Borja J; Olivella P
Med Clin (Barc); 2000 Nov; 115(15):583-6. PubMed ID: 11141394
[No Abstract] [Full Text] [Related]
19. Improving outcomes in acute coronary syndromes--the FRISC II trial.
Kontny F
Clin Cardiol; 2001 Mar; 24(3 Suppl):I3-7. PubMed ID: 11286312
[TBL] [Abstract][Full Text] [Related]
20. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina.
Montalescot G; Collet JP; Lison L; Choussat R; Ankri A; Vicaut E; Perlemuter K; Philippe F; Drobinski G; Thomas D
J Am Coll Cardiol; 2000 Jul; 36(1):110-4. PubMed ID: 10898421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
